Seminars in Nephrology
Volume 24, Issue 5 , Pages 441-445 , September 2004

Chronic systemic inflammation in uremia: Potential therapeutic approaches

  • Gianfranco Guarnieri

      Affiliations

    • Clinica Medica, Department of Clinical, Morphological and Technological Services, University of Trieste, Trieste, Italy
    • Corresponding Author InformationAddress reprint requests to Gianfranco Guarnieri, MD, Clinica Medica, Ospedale Cattinara, Strada di Fiume 447, 34100 Trieste, Italy
    • ,
  • Gianni Biolo

      Affiliations

    • Clinica Medica, Department of Clinical, Morphological and Technological Services, University of Trieste, Trieste, Italy
    • ,
  • Michela Zanetti

      Affiliations

    • Clinica Medica, Department of Clinical, Morphological and Technological Services, University of Trieste, Trieste, Italy
    • ,
  • Rocco Barazzoni

      Affiliations

    • Clinica Medica, Department of Clinical, Morphological and Technological Services, University of Trieste, Trieste, Italy

References 

  1. Choy EHS , Panayi GS . Cytokine pathways and joint inflammation in rheumatoid arthritis . N Engl J Med . 2001;344:907–916
  2. Hotchkiss RS , Karl IE . The pathophysiology and treatment of sepsis . N Engl J Med . 2003;348:138–150
  3. Brockhaus M , Bar-Khayim Y , Gurwicz S , et al.   Plasma tumor necrosis factor soluble receptors in chronic renal failure . Kidney Int . 1992;42:663–667
  4. Kaysen G , Kumar V . Inflammation in ESRD (Causes and potential consequences) . J Ren Nutr . 2003;13:158–160
  5. Guarnieri G , Toigo G , Fiotti N , et al.   Mechanisms of malnutrition in uremia . Kidney Int . 1997;62(suppl):S41–S44
  6. Ikizler TA , Wingard RL , Harvell J , et al.   Association of morbidity with markers of nutrition and inflammation in chronic hemodialysis patients (A prospective study) . Kidney Int . 1999;55:1945–1951
  7. Guarnieri G , Antonione R , Biolo G . Mechanisms of malnutrition in uremia . J Ren Nutr . 2003;13:153–157
  8. Stenvinkel P . Inflammatory and atherosclerotic interactions in the depleted uremic patient . Blood Purif . 2001;19:53–61
  9. Arici M , Walls M . End-stage renal disease, atherosclerosis, and cardiovascular mortality (Is C-reactive protein the missing link?) . Kidney Int . 2001;59:407–414
  10. Girndt M , Kaul H , Sester U , et al.   Anti-inflammatory interleukin-10 genotype protects dialysis patients from cardiovascular events . Kidney Int . 2002;62:949–955
  11. Garibotto G , Russo R , Sofia A , et al.   Skeletal muscle protein synthesis and degradation in patients with chronic renal failure . Kidney Int . 1994;45:1432–1439
  12. Marette A . Mediators of cytokine-induced insulin resistance in obesity and other inflammatory settings . Clin Nutr Metab Care . 2002;5:377–383
  13. Memoli B , Postiglione L , Cianciaruso B , et al.   Role of different dialysis membranes in the release of interleukin-6-soluble receptor in uremic patients . Kidney Int . 2000;58:417–424
  14. Freemont AJ . The pathology of dialysis . Semin Dial . 2002;15:227–231
  15. Kalousova M , Zima T , Tesar V , et al.   Relationship between advanced glycoxidation end products, inflammatory markers/acute-phase reactants, and some autoantibodies in chronic hemodialysis patients . Kidney Int . 2003;84(suppl):S62–S64
  16. Descamps-Latscha B , Jungers P , Witko-Sarsat V . Immune system dysregulation in uremia (Role of oxidative stress) . Blood Purif . 2002;20:481–484
  17. Mezzano D , Pais EO , Aranda E , et al.   Inflammation, not hyperhomocysteinemia, is related to oxidative stress and hemostatic and endothelial dysfunction in uremia . Kidney Int . 2001;60:1844–1850
  18. Paniagua R , Frias Y , de Ventura MJ , et al.   C-reactive protein and anti-Chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis . Perit Dial Int . 2003;23:132–137
  19. Heart Protection Study Collaborative Group . MRC/BHF heart protection study of cholesterol lowering with simvastatin in 20,536 high-risk individuals (A randomised placebo-controlled trial) . Lancet . 2002;360:7–22
  20. Lindmark E , Siegbahn A . Tissue factor regulation and cytokine expression in monocyte-endothelial cell co-cultures. Effects of a statin, an ACE-inhibitor and a low-molecular-weight heparin . Thromb Res . 2002;108:77–84
  21. Zelvyte I , Dominaitiene R , Crisby M , et al.   Modulation of inflammatory mediators and PPARγ and NFκB expression by pravastatin in response to lipoproteins in human monocytes in vitro . Pharmacol Res . 2002;45:147–154
  22. Plenge JK , Hernandez TL , Weil KM , et al.   Simvastatin lowers C-reactive protein within 14 days (An effect independent of low-density lipoprotein cholesterol reduction) . Circulation . 2002;106:1447–1452
  23. Koh KK , Son JW , Ahn JY , et al.   Comparative effects of diet and statin on NO bioactivity and matrix metalloproteinases in hypercholesterolemic patients with coronary artery disease . Arterioscler Thromb Vasc Biol . 2002;22:19–23
  24. Chang JW , Yang WS , Min WK , et al.   Effects of simvastatin on high sensitivity C-reactive protein and serum albumin in hemodialysis patients . Am J Kidney Dis . 2002;39:1213–1217
  25. van den Akker JM , Bredie SJ , Diepenveen SH , et al.   Atorvastatin and simvastatin in patients on hemodialysis (Effects on lipoproteins, C-reactive protein and in vivo oxidized LDL) . J Nephrol . 2003;16:238–244
  26. Kranzhofer R , Browatzki M , Schmidt J , et al.   Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes . Biochem Biophys Res Commun . 1999;257:826–828
  27. Guo G , Morrissey J , McCracken R , et al.   Contributions of angiotensin II and tumor necrosis factor-alpha to the development of renal fibrosis . Am J Physiol . 2001;280:F777–F785
  28. Tsutamoto T , Wada A , Maeda K , et al.   Angiotensin II type 1 receptor antagonist decreases plasma levels of tumor necrosis factor alpha, interleukin-6 and soluble adhesion molecules in patients with chronic heart failure . J Am Coll Cardiol . 2000;35:714–721
  29. Navalkar S , Parthasarathy S , Santanam N , et al.   Irbesartan, an angiotensin type 1 receptor inhibitor, regulates markers of inflammation in patients with premature atherosclerosis . J Am Coll Cardiol . 2001;37:440–444
  30. Stenvinkel P , Andersson P , Wang T , et al.   Do ACE-inhibitors suppress tumour necrosis factor-alpha production in advanced chronic renal failure . J Intern Med . 1999;246:503–507
  31. Noel P , Nelson S , Bokulic R , et al.   Pentoxifylline inhibits lipopolysaccharide-induced serum tumor necrosis factor and mortality . Life Sci . 1990;47:1023–1029
  32. Breuillé D , Farge MC , Rosé F , et al.   Pentoxifylline decreases body weight loss and muscle protein wasting characteristics of sepsis . Am J Physiol . 1993;265:E660–E666
  33. Biolo G , Ciocchi B , Bosutti A , et al.   Pentoxifylline acutely reduces protein catabolism in chronically uremic patients . Am J Kidney Dis . 2002;40:1162–1172
  34. Beattie MS , Shlipak MG , Liu H , et al.   C-reactive protein and ischemia in users and nonusers of beta-blockers and statins (Data from the Heart and Soul Study) . Circulation . 2003;107:245–250
  35. Gullestad L , Semb AG , Holt E , et al.   Effect of thalidomide in patients with chronic heart failure . Am Heart J . 2002;144:847–850
  36. Endres S , Ghorbani R , Kelley VE , et al.   The effect of dietary supplementation with n-3 polyunsaturated fatty acids on the synthesis of interleukin-1 and tumor necrosis factor by mononuclear cells . N Engl J Med . 1989;320:265–271
  37. Simopoulos AP . Omega-3 fatty acids in inflammation and autoimmune diseases . J Am Coll Nutr . 2002;21:495–505
  38. Donadio JV , Bergstralh EJ , Offord KP , et al.  Mayo Nephrology Collaborative Group   A controlled trial of fish oil in IgA nephropathy . N Engl J Med . 1994;331:1194–1199
  39. Ando M , Sanaka T , Nihei H . Eicosapentanoic acid reduces plasma levels of remnant lipoproteins and prevents in vivo peroxidation of LDL in dialysis patients . J Am Soc Nephrol . 1999;10:2177–2184
  40. Cappelli P , Di Liberato L , Stuard S , et al.   N-3 polyunsaturated fatty acid supplementation in chronic progressive renal disease . J Nephrol . 1997;10:157–162
  41. Vermeersch P , Nong Z , Stabile E , et al.   L-arginine administration reduces neointima formation after stent injury in rats by a nitric oxide-mediated mechanism . Arterioscler Thromb Vasc Biol . 2001;21:1604–1609
  42. Vos IH , Rabelink TJ , Dorland B , et al.   L-arginine supplementation improves function and reduces inflammation in renal allografts . J Am Soc Nephrol . 2001;12:361–367
  43. Reyes AA , Karl IE , Kissane J , et al.   L-arginine administration prevents glomerular hyperfiltration and decreases proteinuria in diabetic rats . J Am Soc Nephrol . 1993;4:1039–1045
  44. Reckelhoff JF , Kellum JA , Racusen LC , et al.   Long-term dietary supplementation with L-arginine prevents age-related reduction in renal function . Am J Physiol . 1997;272:R1768–R1774
  45. Schramm L , La M , Heidbreder E , et al.   L-arginine deficiency and supplementation in experimental acute renal failure and in human kidney transplantation . Kidney Int . 2002;61:1423–1432
  46. Wever R , Boer P , Hijmering M , et al.   Nitric oxide production is reduced in patients with chronic renal failure . Arterioscler Thromb Vasc Biol . 1999;19:1168–1172
  47. De Caterina R , Libby P , Peng HB , et al.   Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines . J Clin Invest . 1995;96:60–68
  48. Eid HM , Eritsland J , Larsen J , et al.   Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin . Atherosclerosis . 2003;166:279–284
  49. Kielstein JT , Boger RH , Bode-Boger SM , et al.   Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease (Relationship to treatment method and atherosclerotic disease) . J Am Soc Nephrol . 1999;10:594–600
  50. Zoccali C , Benedetto FA , Maas R , et al.   Asymmetric dimethylarginine, C-reactive protein, and carotid intima-media thickness in end-stage renal disease . J Am Soc Nephrol . 2002;13:490–496
  51. Zhong Z , Wheeler MD , Li X , et al.   L-glycine (A novel antiinflammatory, immunomodulatory, and cytoprotective agent) . Curr Opin Clin Nutr Metab Care . 2003;6:229–240
  52. Thomsen K , Nielsen CB , Flyvbjerg A . Effects of glycine on glomerular filtration rate and segmental tubular handling of sodium in conscious rats . Clin Exp Pharmacol Physiol . 2002;29:449–454
  53. Yin M , Zhong Z , Connor HD , et al.   Protective effect of glycine on renal injury induced by ischemia-reperfusion in vivo . Am J Physiol . 2002;282:F417–F423
  54. Winter BK , Fiskum G , Gallo LL . Effects of L-carnitine on serum triglyceride and cytokine levels in rat models of cachexia and septic shock . Br J Cancer . 1995;72:1173–1179
  55. Vescovo G , Ravara B , Gobbo V , et al.   L-carnitine (A potential treatment for blocking apoptosis and preventing skeletal muscle myopathy in heart failure) . Am J Physiol . 2002;283:C802–C810
  56. Guarnieri G , Situlin R , Biolo G . Carnitine metabolism in uremia . Am J Kidney Dis . 2001;38(suppl):S63–S67
  57. Vesela E , Racek J , Trefil L , et al.   Effect of L-carnitine supplementation in hemodialysis patients . Nephron . 2001;88:218–223
  58. Pedersen BK , Bruunsgaard H . Possible beneficial role of exercise in modulating low-grade inflammation in the elderly . Scand J Med Sci Sports . 2003;13:56–62
  59. Esposito K , Pontillo A , Di Palo C , et al.   Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women (A randomized trial) . JAMA . 2003;289:1799–1804
  60. Greiwe JS , Cheng B , Rubin DC , et al.   Resistance exercise decreases skeletal muscle tumor necrosis factor alpha in frail elderly humans . FASEB J . 2001;15:475–482

PII: S0270-9295(04)00090-7

doi: 10.1016/j.semnephrol.2004.06.007

Seminars in Nephrology
Volume 24, Issue 5 , Pages 441-445 , September 2004

Article Tools

* Image Usage & Resolution